Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Protara Therapeutics Inc.

JonesTrading analyst Soumit Roy maintained a Buy rating on Protara Therapeutics today and set a price target of $25.00. Roy covers the Healthcare s...

JonesTrading Remains a Buy on Protara Therapeutics (TARA)

Oppenheimer analyst reiterated a Buy rating on Protara Therapeutics today and set a price target of $25.00. In addition to Oppenheimer, Protara The...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TARA	$5.22	+1.46%	359.18K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TARA	$5.22	+1.5%	359.18K
3
4
5
6

TARA

TARA

Get Protara Therapeutics Inc. Data in Excel

Get Protara Therapeutics Inc. Data in Excel